Celladon Corporation Report issue

For profit Phase 2
Founded: La Jolla CA United States (2000)
Status: Acquired by Eiger BioPharmaceuticals (2015)

Organization Overview

First Clinical Trial
2007
NCT00454818
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

aav1/serca2a (2 trials)

mydicar (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Heart Failure (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2